Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

Evolution of Acridines and Xanthenes as a Core Structure for the Development of Antileishmanial Agents

(2022) Carlos F. M. Silva et al.   Pharmaceuticals

Sand flies: Basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites

(2022) Pedro Cecílio et al.   Communications Biology

Validation of a mixture of rK26 and rK39 antigens from Iranian strain of Leishmania infantum to detect anti-Leishmania antibodies in human and reservoir hosts

(2022) Bibi Razieh Hosseini Farash et al.   Scientific Reports

Clinical criteria for Mucosal Leishmaniasis diagnosis in rural South America: A systematic literature review

(2022) Jacob M. Bezemer et al.   PLoS Neglected Tropical Diseases

Leishmania guyanensis suppressed inducible nitric oxide synthase provoked by its viral endosymbiont

(2022) Dmitry Kopelyanskiy et al.   Frontiers in Cellular and Infection Microbiology

Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different Leishmania spp. in Brazil

(2022) Rayana Carla Silva de Morais et al.   EXPERIMENTAL PARASITOLOGY

Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs

(2022) Malcolm S. Duthie et al.   Pathogens

Expression of Concern: Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen

(2021)   PLoS Neglected Tropical Diseases

A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice

(2021) Thais Lopes Valentim Di Paschoale Ostolin et al.   VACCINE

Revival of Leishmanization and Leishmanin

(2021) Thalia Pacheco-Fernandez et al.   Frontiers in Cellular and Infection Microbiology

Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis – A review

(2021) Pragya Prasanna et al.   BIOMEDICINE & PHARMACOTHERAPY

Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre‐Clinical to Clinical Findings

(2021) Wanessa Santana et al.   CHEMISTRY & BIODIVERSITY

From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

(2021) Greta Volpedo et al.   Expert Review of Vaccines

PpSP32-like protein as a marker of human exposure to Phlebotomus argentipes in Leishmania donovani foci in Bangladesh

(2021) Petra Sumova et al.   INTERNATIONAL JOURNAL FOR PARASITOLOGY

Immune Responses in Cutaneous Leishmaniasis: in vitro Thelper1/Thelper2 Cy-tokine Profiles Using Live Versus Killed Leishmania major

(2021) Akram Miramin-Mohammadi et al.   Iranian Journal of Arthropod-Borne Diseases

Intranasal immunization with chitosan microparticles enhances lack-dna vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis

(2021) Daniel Claudio Oliveira Gomes et al.   MICROBES AND INFECTION

Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice

(2021) Deepak Kumar Goyal et al.   MICROBIAL PATHOGENESIS

Detection of Leishmania tarentolae in lizards, sand flies and dogs in southern Italy, where Leishmania infantum is endemic: hindrances and opportunities

(2021) Jairo Alfonso Mendoza-Roldan et al.   Parasites & Vectors

Human leishmaniasis vaccines: Use cases, target population and potential global demand

(2021) Stefano Malvolti et al.   PLoS Neglected Tropical Diseases

Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis

(2021) Doumet Georges Helou et al.   PLoS Neglected Tropical Diseases

Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis

(2021) Subir Karmakar et al.   Communications Biology

Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies

(2021) Mirosława Panasiuk et al.   Microbial Cell Factories

Immunogenicity and potential protection of DNA vaccine of Leishmania martiniquensis against Leishmania infection in mice

(2021) Thuntawat Aunguldee et al.   Journal of Infection in Developing Countries

Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action

(2021) Jorge Alvar et al.   Lancet Global Health

Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development

(2021) Greta Volpedo et al.   Frontiers in Immunology

Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy

(2020) Rita Velez et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice

(2020) Elaheh Davarpanah et al.   PLoS Neglected Tropical Diseases

Development and Characterization of an Avirulent Leishmania major Strain

(2020) Mukesh Kumar Jha et al.   JOURNAL OF IMMUNOLOGY

A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing

(2020) Wen-Wei Zhang et al.   Nature Communications

A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection

(2020) Daniela P. Lage et al.   npj Vaccines

Leishmania Immunity: Advancing Immunotherapy and Vaccine Development

(2020) Nnamdi M. Ikeogu et al.   Microorganisms

Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB-CTE Antigens against Visceral Leish-maniasis in Syrian Hamster as Preliminary Study

(2020) Yasaman TASLIMI et al.   Iranian Journal of Parasitology

Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host

(2019) Stephan Klatt et al.   PLoS Neglected Tropical Diseases

The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice

(2019) Marcus Vinícius Alves-Silva et al.   Frontiers in Immunology

Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections

(2019) Leroy Versteeg et al.   Vaccines

An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines

(2019) Mehdi Mohebali et al.   ACTA TROPICA

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

(2018) Fabiana Alves et al.   CLINICAL MICROBIOLOGY REVIEWS

Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani

(2018) Malcolm S. Duthie et al.   Frontiers in Immunology

Nanoparticle Vaccines Against Infectious Diseases

(2018) Rashmirekha Pati et al.   Frontiers in Immunology

Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis

(2017) Maritsa Margaroni et al.   International Journal of Nanomedicine

Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines

(2017) Ans De Beuckelaer et al.   TRENDS IN MOLECULAR MEDICINE

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

(2017) Mohamed Osman et al.   PLoS Neglected Tropical Diseases

Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis

(2017) Pedro Cecílio et al.   PLoS Neglected Tropical Diseases

A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against Experimental Visceral Leishmaniasis

(2017) Evita Athanasiou et al.   Frontiers in Immunology

Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection

(2017) Anna Paula V. Moura et al.   ACS Central Science

Possibilities and challenges for developing a successful vaccine for leishmaniasis

(2016) Saumya Srivastava et al.   Parasites & Vectors

Status of vaccine research and development of vaccines for leishmaniasis

(2016) Portia M. Gillespie et al.   VACCINE

Cutaneous Leishmaniasis Vaccination: A Matter of Quality

(2016) Paula Mello De Luca et al.   Frontiers in Immunology

A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates

(2015) Fabiano Oliveira et al.   Science Translational Medicine

Therapeutic vaccines for leishmaniasis

(2014) Ali Khamesipour   EXPERT OPINION ON BIOLOGICAL THERAPY

Mortality and Case Fatality Due to Visceral Leishmaniasis in Brazil: A Nationwide Analysis of Epidemiology, Trends and Spatial Patterns

(2014) Francisco Rogerlândio Martins-Melo et al.   PLoS One

Live Vaccination Tactics: Possible Approaches for Controlling Visceral Leishmaniasis

(2014) Noushin Saljoughian et al.   Frontiers in Immunology

Biomarkers of Safety and Immune Protection for Genetically Modified Live Attenuated Leishmania Vaccines Against Visceral Leishmaniasis – Discovery and Implications

(2014) Sreenivas Gannavaram et al.   Frontiers in Immunology

Dual effect of Lutzomyia longipalpis saliva on Leishmania braziliensis infection is mediated by distinct saliva-induced cellular recruitment into BALB/c mice ear

(2013) Vanessa Carregaro et al.   BMC MICROBIOLOGY

Live Attenuated Leishmania donovani p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB/c Mice

(2013) R. Dey et al.   JOURNAL OF IMMUNOLOGY

Case study for a vaccine against leishmaniasis

(2013) Jorge Alvar et al.   VACCINE

Use of a LiESP/QA-21 Vaccine (CaniLeish) Stimulates an Appropriate Th1-Dominated Cell-Mediated Immune Response in Dogs

(2012) Javier Moreno et al.   PLoS Neglected Tropical Diseases

Vaccine candidates for leishmaniasis: A review

(2011) Rajeev Nagill et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation

(2011) Javier Carrión et al.   Parasites & Vectors

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

(2011) Jaya Chakravarty et al.   VACCINE

The development and clinical evaluation of second-generation leishmaniasis vaccines

(2011) Malcolm S. Duthie et al.   VACCINE

Cytokines and Their STATs in Cutaneous and Visceral Leishmaniasis

(2010) Hannah E. Cummings et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

UDP-Gal: N-acetylglucosamine β 1–4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis

(2008) Siddhartha Kumar Bhaumik et al.   GLYCOCONJUGATE JOURNAL

Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil

(2008) G.P. Borja-Cabrera et al.   VACCINE

Despite Leishvaccine and Leishmune® trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis

(2008) Márcio Sobreira Silva Araújo et al.   VACCINE

Leishmania infantum: Prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice

(2007) Sima Rafati et al.   EXPERIMENTAL PARASITOLOGY